BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KESHO - ECPv6.18.3.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:KESHO
X-ORIGINAL-URL:https://kesho-kenya.org
X-WR-CALDESC:Events for KESHO
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Africa/Nairobi
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:EAT
DTSTART:20180101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20200929T190000
DTEND;TZID=Africa/Nairobi:20200929T203000
DTSTAMP:20211024T154727Z
CREATED:20210604T163946Z
LAST-MODIFIED:20211024T154727Z
UID:5302-1601406000-1601411400@kesho-kenya.org
SUMMARY:Management of Hormone Receptor Positive Breast Cancer
DESCRIPTION:[vc_row][vc_column]    \n    	\n                	Webinar Recording                \n        \n    \n    [vc_column_text] \n[vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"]    	\n        Access our Membership Page        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Fill in the Membership Form        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Access Membership Portal        \n        [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n\n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/management-of-hormone-receptor-positive-breast-cancer/
LOCATION:Virtual Event (Zoom)\, Kenya
CATEGORIES:CME 2020,Webinar Recording Available
ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2021/06/image_2021-06-04_193725.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20200915T191500
DTEND;TZID=Africa/Nairobi:20200915T203000
DTSTAMP:20211024T154755Z
CREATED:20210817T111009Z
LAST-MODIFIED:20211024T154755Z
UID:5918-1600197300-1600201800@kesho-kenya.org
SUMMARY:Management of Neuroendocrine Tumors
DESCRIPTION:[vc_row][vc_column][vc_column_text] \n\n\n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]Moderator: Dr. Sitna Mwanzi \nSponsor: Novartis \nPresenters: \n\nNjoki Njiraini\, a consultant clinical oncologist based at the Cancer Centre in Kenyatta University Teaching Research and Referral Hospital.\n\nNeuroendocrine Neoplasms arise from diffuse neuroendocrine cells in the body and are broadly divided into well-differentiated neuroendocrine tumors (NETs)\, including the sporadic small intestine\, pancreatic\, thorax\, and thymus NETs\, and poorly differentiated neuroendocrine carcinomas (NECs)\, classified based on differentiation\, Ki67 levels\, and mitotic figures. NETs arise from neuroendocrine cells throughout the body. There has been increasing incidence over the last 15 years\, with a male preponderance and a more adverse outcome. Diagnosis is mainly through histology and immunohistochemistry. Staging for NECs is mainly by adenocarcinoma staging system\, which mainly involves imaging through CT scan\, MRI\, Contrast-Enhanced USS\, endoscopic USS\, and functional imaging. Treatment is dependent on TNM staging and grading of the disease and includes surgery\, somatostatin analogs\, hepatic-directed therapies\, and chemotherapeutics. For a patient with carcinoid syndrome\, the short-acting octreotide can be considered first\, while waiting for long-acting octreotide to act. Locally\, therapies are available in 20 mg from Novartis retailing at 68000 Kenya shillings\, but 30mg are also available in the market through other distributors. The toxicity profiles should be put into consideration e.g. diarrhea\, although sometimes it’s difficult to differentiate drugs’ side effects from the initial tumor signs. Neuroendocrine carcinomas are classified as small or large cells and mostly the patients have poor outcomes. There is a need to improve imaging and multidisciplinary teams to share local experiences of neuroendocrine patients.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column]    \n    	\n                	Webinar Recording                \n        \n    \n    [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"]    	\n        Access our Membership Page        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Fill in the Membership Form        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Access Membership Portal        \n        [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n\n\n\n\n\n\n\n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/management-of-neuroendocrine-tumors-2/
CATEGORIES:CME 2020,Webinar Recording Available
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210813_171140.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20200908T191500
DTEND;TZID=Africa/Nairobi:20200908T203000
DTSTAMP:20211024T154816Z
CREATED:20210817T105953Z
LAST-MODIFIED:20211024T154816Z
UID:5914-1599592500-1599597000@kesho-kenya.org
SUMMARY:Management of Iron Overload
DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr. Paresh Dave \nSponsor: Novartis \nPresenters: \n\nPeter Oyiro\, Medical Oncologist Kenyatta National Hospital Teaching and Referral Hospital\n\nIron overload is a poly etiologic condition characterized by a moderate to severe increase in the body iron that has or will have negative effects secondary to iron deposition in tissues or body organs. It may be hereditary or acquired. It is important to detect the disease before organ damage occurs. Iron overload affects overall survival partly due to the underlying biology of the disease but also because of the sequelae of iron overload\, including cardiomyopathy\, cardiac events\, liver disease\, and the development of diabetes. For patients with higher serum ferritin levels\, the 100-day post-transplant mortality is worse with inferior overall survival (OS) and a higher rate of graft vs host disease.  Therefore\, iron chelation therapy can improve OS and is effective at reducing serum ferritin levels\, cardiac events\, and diabetes in patients with blood-transfusion-related iron overload. Compliance is highly encouraged to realize successful treatment. The safety profile of each chelator should be evaluated before the initiation of treatment. Patients receiving chemotherapy and who have a drop in blood count parameters require evaluation to find out the causes. Iron studies are required to generate more data. Iron supplementary can be toxic. Patients with severe organ dysfunction can have a combination of iron chelation therapy.  Ferritin levels should be done every 3 months.  Iron chelation OS is not contraindicated in HIV patients with evidence of iron overload.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column]    \n    	\n                	Webinar Recording                \n        \n    \n    [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"]    	\n        Access our Membership Page        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Fill in the Membership Form        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Access Membership Portal        \n        [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/management-of-iron-overload/
CATEGORIES:CME 2020,Webinar Recording Available
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210813_170945.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20200827T070000
DTEND;TZID=Africa/Nairobi:20200827T203000
DTSTAMP:20211024T154948Z
CREATED:20210604T162505Z
LAST-MODIFIED:20211024T154948Z
UID:5294-1598511600-1598560200@kesho-kenya.org
SUMMARY:Cancer and Thrombosis Current Perspective
DESCRIPTION:[vc_row][vc_column]    \n    	\n                	Webinar Recording                 \n        \n    \n    [vc_column_text] \n[vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"]    	\n        Access our Membership Page        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Fill in the Membership Form        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Access Membership Portal        \n        [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n\n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/cancer-and-thrombosis-current-perspective/
LOCATION:Virtual Event (Zoom)\, Kenya
CATEGORIES:CME 2020,Webinar Recording Available
ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2021/06/image_2021-06-04_193129.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20200811T191500
DTEND;TZID=Africa/Nairobi:20200811T201500
DTSTAMP:20250622T142511Z
CREATED:20210813T143324Z
LAST-MODIFIED:20250622T142511Z
UID:5898-1597173300-1597176900@kesho-kenya.org
SUMMARY:Emerging Therapies in Hodgkin's Lymphoma Management - Treatment Beyond The Basics
DESCRIPTION:[vc_row][vc_column][vc_column_text] \nModerator: Dr. Miriam Mutebi \nSponsor: Takeda\, a pharmaceutical company with a patient assistance program for Hodgkin’s lymphoma in Kenya. \nPresenters: \n\nDr. Anna Sureda\, Head of the Clinical Hematology Department and the Stem Cell Transplantation program of Institut Catala d’Oncologia – Hospitalet\, Barcelona\n\nHodgkin’s lymphoma (HL) is one of the most curable hematological malignancies with first-line treatment\, which is a combination of radiotherapy and chemotherapy. Autologous hematopoietic stem cell transplantation (auto-HCT) is the standard therapy for HL patients relapsing after first-line chemotherapy. The use of allogeneic stem cell transplantation (ASCT) has improved the overall survival (OS) of patients over time.  To improve the landscape of chemotherapy treatment for refractory disease\, a new drug\, Brentuximab vedotin\, has been introduced. This drug is an antibody-drug conjugate (ADC) consisting of 3 components; it binds to CD30 forming a complex that is internalized and traffics to the lysosome. The drug was granted accelerated approval by the US FDA in 2011.  The European Medicines Agency (EMA) approved this drug in 2012 for the treatment of adult patients with relapsed or refractory CD30+ HL\, anaplastic large cell lymphoma\, and those at increased risk of relapse or progression following ASCT. The efficacy reported as median observation time from the first dose at study closure was 35.1 months (1.8-72.9). Studies revealed that Brentuximab vedotin and ESHAP are highly effective as second-line therapy for Hodgkin’s patients. Brentuximab vedotin was the first targeted therapy that was tested in patients with relapsed/refractory HL. It was very effective as a single drug in patients that relapse or progress after auto-HCT. Brentuximab vedotin is able to potentially increase the number of patients that are candidates to auto-HCT. It improves progression-free survival (PFS) in those patients with a high risk of relapse after auto-HCT when used as a consolidation strategy. It has demonstrated an adequate and safe toxicity profile\, even in HIV-positive patients with HL. Brentuximab vedotin is being used in other settings with very interesting results (RR setting in combination with chemotherapy\, first line). However\, the cost of the treatment in Kenya is quite high; a single vial costs Kshs. 330\,000. A patient assistance program in partnership with Takeda is helping patients in Kenya who cannot afford to pay\, to complete their treatment. Although this program is run in private hospitals\, physicians seeing patients at public facilities can refer the patients to the private facilities for assistance\, but continue to follow up on the patients. \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column]    \n    	\n                	Webinar Recording                \n        \n    \n    [vc_column_text] \n[vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"]    	\n        Access our Membership Page        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Fill in the Membership Form        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Access Membership Portal        \n        [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n\n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/emerging-therapies-in-hodgkins-lymphoma-management-treatment-beyond-the-basics/
CATEGORIES:CME 2020,Webinar Recording Available
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210813_170809.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20200730T191500
DTEND;TZID=Africa/Nairobi:20200730T203000
DTSTAMP:20250622T142511Z
CREATED:20210810T101728Z
LAST-MODIFIED:20250622T142511Z
UID:5839-1596136500-1596141000@kesho-kenya.org
SUMMARY:Ovarian Cancer\, The Good\, The Bad\, And The Ugly
DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr. Andrew Odhiambo\, Consultant Medical Oncologist & Lecturer\, University of Nairobi \nSponsor: Merck \nPresenters: \n\nDr. Benjamin Odongo Elly\, Gynecologic Oncologist at Moi Teaching and Referral University.\n\nMoi Teaching and Referral Hospital (MTRH) cancer center offers a holistic approach to cancer treatment. Germ cell tumors account for 10-115% of all ovarian tumors and affect young females of reproductive age. They are very chemosensitive hence are curable\, using fertility-sparing surgery. Stromal tumors account for 3-5% of all ovarian tumors and affect women of all ages. These tumors are diagnosed early and are histologically low-grade\, with a good prognosis\, when treated with surgery\,  followed by adjuvant treatment. However\, some tumors are aggressive and lethal. Epithelial tumors represent 80-85% of all ovarian tumors. They have a poor prognosis and are always detected late. Warning signs include abdominal bloating\, abdominal/pelvic pain\, bowel/bladder symptoms\, and irregular vaginal bleeding. Prevention of ovarian cancer is by avoidance of risk factors and prophylactic surgery in high-risk women. There is currently no good screening test for the general population. Diagnosis is by appropriate physical examination\, pelvic/transvaginal ultrasound\, tumor markers\, and CT scan. The majority of patients are diagnosed with advanced-stage disease (stage III or IV) leading to poor overall 5-year survival. However\, patients are living longer with the disease due to advances in surgery and chemotherapy treatment. As a country\, there is a need to improve the early diagnosis of ovarian cancer through advocacy\, patient education\, human resource\, training capacity building\, and availing resources to the health care facilities.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"]    	\n        Access our Membership Page        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Fill in the Membership Form        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Access Membership Portal        \n        [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/ovarian-cancer-the-good-the-bad-and-the-ugly/
LOCATION:Virtual Event (Zoom)\, Kenya
CATEGORIES:CME 2020,Webinar Recording Available
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20191121T200000
DTEND;TZID=Africa/Nairobi:20191121T220000
DTSTAMP:20250622T142511Z
CREATED:20210420T152935Z
LAST-MODIFIED:20250622T142511Z
UID:4731-1574366400-1574373600@kesho-kenya.org
SUMMARY:TOPIC: Management of Brain Tumors
DESCRIPTION:[vc_row][vc_column][vc_column_text] \nFinally\, KESHO partnered with the Neurological Society of Kenya to discuss the management of brain tumors with a stimulating surgical perspective from Dr Edwin Mogere Neurosurgeon and an in-depth discussion of management of medical symptoms from brain tumors by Dr Judy Kwasa Neurologist. \n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/topic-management-of-brain-tumors/
LOCATION:Crowne Plaza Hotel
CATEGORIES:CME 2019,Webinar Recording Available
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20190829T200000
DTEND;TZID=Africa/Nairobi:20190829T220000
DTSTAMP:20250622T142511Z
CREATED:20210420T153545Z
LAST-MODIFIED:20250622T142511Z
UID:4736-1567108800-1567116000@kesho-kenya.org
SUMMARY:TOPIC: BCR-ABL and OSTEOGENIC SARCOMA
DESCRIPTION:[vc_row][vc_column][vc_column_text]We took a well-deserved break in July 2019 and came back in August for a mixed presentation on CML and osteogenic sarcoma from Prof Nicholas Abinya Medical Oncologist and Dr Mohammed Ezzi Medical Oncologist. The outcome for patients with CML has significantly improved with TKI therapies\, yet challenges persist in adequate monitoring which is expensive. The lack of co-ordinated multidisciplinary care needed for osteogenic sarcoma led to many lost to follow up and incomplete treatments with poor outcomes. MDTs prior to treatment is a potential strategy for reversing this trend.[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/topic-bcr-abl-and-osteogenic-sarcoma/
LOCATION:Sarova Panafric Hotel\, Nairobi\, Kenya.\, Kenya
CATEGORIES:CME 2019,Continuing Medical Education (CME)
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20190829T170000
DTEND;TZID=Africa/Nairobi:20190829T200000
DTSTAMP:20250622T142510Z
CREATED:20210420T153328Z
LAST-MODIFIED:20250622T142510Z
UID:4734-1567098000-1567108800@kesho-kenya.org
SUMMARY:SSA Breast Cancer
DESCRIPTION:[vc_row][vc_column][vc_column_text]Another busy month for us with three meetings in October. First off\, Prof Asim Jamal Medical Oncologist gave an excellent overview of presentation\, diagnosis and management of neuroendocrine tumors which are not as rare as originally felt. KESHO then partnered with Pathologists Lancet Kenya to discuss molecular diagnostics in hemato-oncology. Speakers from France and our very own experts deliberated on the changing landscape of hemato-oncology and what is practical in our setting. Finally\, a multidisciplinary webinar session on breast cancer concluded our sessions for the month in recognition of the Breast Cancer Awareness month\, with presentations from Dr. Gladwell Kiarie Medical Oncologist\, Dr. Fred Okuku Medical Oncologist\, Dr. Aba Anoa Scott Radiation/Clinical Oncologist and Prof. Ronald Wasike Breast Surgeon.[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/ssa-breast-cancer/
LOCATION:Sarova Panafric Hotel\, Nairobi\, Kenya.\, Kenya
CATEGORIES:CME 2019
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20190627T110000
DTEND;TZID=Africa/Nairobi:20190627T200000
DTSTAMP:20250622T142511Z
CREATED:20210420T154157Z
LAST-MODIFIED:20250622T142511Z
UID:4738-1561633200-1561665600@kesho-kenya.org
SUMMARY:TOPIC: Paediatric Malignancies; Optimising Care In Acute Leukaemia
DESCRIPTION:[vc_row][vc_column][vc_column_text]We directed our focus on hematology and this time we concentrated on pediatric malignancies. Dr. Jamila Rajab Consultant Haematologist\, Dr. Grace Mbatia Paediatric Oncologist and Dr Festus Njuguna Paediatric Oncologist. We got a glimpse on the myriad challenges our colleagues in hematology face in the management of pediatric hematological malignancies including complicated regimens\, high rate of drop outs and poor supportive care. The outcome was to continue in the process of development of national treatment protocols that can be used which can also help in comparing treatment outcomes in the different settings.[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/topic-paediatric-malignancies-optimising-care-in-acute-leukaemia/
LOCATION:Sarova Panafric Hotel\, Nairobi\, Kenya.\, Kenya
CATEGORIES:CME 2019,Continuing Medical Education (CME)
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20190523T200000
DTEND;TZID=Africa/Nairobi:20190523T220000
DTSTAMP:20250622T142511Z
CREATED:20210420T154450Z
LAST-MODIFIED:20250622T142511Z
UID:4740-1558641600-1558648800@kesho-kenya.org
SUMMARY:TOPIC: Colon Cancer; A Multidisciplinary Approach
DESCRIPTION:[vc_row][vc_column][vc_column_text]This was a busy month for our members with three educational events! Dr. Joe Ruturi Cardiothoracic Surgeon and Dr. Solomon Mutua Clinical Oncologist started off the month with discussions on upper GI cancers\, in particular esophageal cancer. KESHO collaborated with ROCHE in their sub-Saharan MPANGO two-day meeting in which many of our members were speakers. The conference focused on triple negative and HER2 breast cancer\, colon and lung cancer. The month ended with an excellent multidisciplinary meeting on colon cancer spearheaded by our very own past Chair\, Dr. Gladwell Kiarie Medical Oncologist and Dr. Rajendra Chauhan Surgical Oncologist. There was a lot of input from our surgical and radiation colleagues.[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/topic-colon-cancer-a-multidisciplinary-approach/
LOCATION:Radisson Blu\, Upperhill Nairobi\, Nairobi\, Nairobi\, 00100\, Kenya
CATEGORIES:CME 2019,Continuing Medical Education (CME)
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20190427T200000
DTEND;TZID=Africa/Nairobi:20190427T220000
DTSTAMP:20250622T142511Z
CREATED:20210420T155152Z
LAST-MODIFIED:20250622T142511Z
UID:4743-1556395200-1556402400@kesho-kenya.org
SUMMARY:TOPIC: HIV Malignancies Symposium
DESCRIPTION:[vc_row][vc_column][vc_column_text]KESHO held a half-day joint symposium with the HIV Clinicians Society discussing the various aspects of HIV related malignancies and how we can better co-manage these patients for improved outcomes. More local research is needed to understand the true prevalence of a co-diagnosis of HIV and cancer and in particular non-AIDS defining malignancies.[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/topic-hiv-malignancies-symposium/
LOCATION:Movenpick Hotel\, Nairobi
CATEGORIES:CME 2019,Continuing Medical Education (CME)
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20190328T000000
DTEND;TZID=Africa/Nairobi:20190328T235959
DTSTAMP:20250622T142510Z
CREATED:20210421T195426Z
LAST-MODIFIED:20250622T142510Z
UID:4784-1553731200-1553817599@kesho-kenya.org
SUMMARY:Topic: Acute Leukaemia
DESCRIPTION:[vc_row][vc_column][vc_column_text] \nProf. Nicholas Abinya Medical Oncologist and Dr. Anne Mwirigi Haematologist gave stimulating perspectives on their care of patients with AML in a public versus a private setting. This led to discussions on collaborations on improving standards of care in our country and in particular with regards to supportive care and financing. KESHO is now engaging with NHIF and the NCCP to outline a treatment package for these patients that factor other costs apart from direct chemotherapy drugs. \n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/topic-acute-leukaemia/
LOCATION:Sarova Panafric Hotel\, Nairobi\, Kenya.\, Kenya
CATEGORIES:CME 2019,Continuing Medical Education (CME)
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20190228T000000
DTEND;TZID=Africa/Nairobi:20190228T235959
DTSTAMP:20250622T142510Z
CREATED:20210421T200249Z
LAST-MODIFIED:20250622T142510Z
UID:4786-1551312000-1551398399@kesho-kenya.org
SUMMARY:Topic: Updates on Recently Launched Cancer Screening Guidelines
DESCRIPTION:[vc_row][vc_column][vc_column_text]In line with the launch of the Kenya Cancer Screening guidelines\, Dr Andrew Odhiambo Medical Oncologist and Dr Primus Ochieng Clinical Oncologist presented on their perspectives on the new guidelines and their experience in other settings outside of Kenya. The Screening Guidelines is as shown below: \n    \n\n    \n        \n            Loading Viewer... \n        \n    \n    [/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/topic-updates-on-recently-launched-cancer-screening-guidelines/
CATEGORIES:CME 2019,Continuing Medical Education (CME)
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20190131T000000
DTEND;TZID=Africa/Nairobi:20190131T235959
DTSTAMP:20250622T142510Z
CREATED:20210421T200621Z
LAST-MODIFIED:20250622T142510Z
UID:4791-1548892800-1548979199@kesho-kenya.org
SUMMARY:Topic: Updates in Breast Cancer Management
DESCRIPTION:[vc_row][vc_column][vc_column_text] \nWe started off the year discussing the most common cancer in women in Kenya and worldwide with two presentations. Dr Miriam Mutebi Surgical Oncologist gave an update on the surgical techniques of breast cancer management and Dr Njoki Njiriani Clinical Oncologist talking on new therapies for advanced hormone positive breast cancer \n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/topic-updates-in-breast-cancer-management/
LOCATION:Sarova Panafric Hotel\, Nairobi\, Kenya.\, Kenya
CATEGORIES:CME 2019,Continuing Medical Education (CME)
END:VEVENT
END:VCALENDAR